Centre for Laboratory Services and Research

The Food and Drugs Authority (FDA) Ghana's Centre for Laboratory Services and Research (CLSR) stands as a cornerstone of public health protection and regulatory enforcement in the West African sub-region. Operating under the comprehensive mandate of the Public Health Act, 2012 (Act 851), the CLSR provides critical testing services across a broad spectrum of regulated products, including food, drugs, cosmetics, and medical devices. Its six specialized laboratories are accredited to ISO/IEC 17025:2017 standards, with its Drug Physicochemical Laboratory notably achieving World Health Organization (WHO) Prequalification status in 2022. This significant achievement not only validates the laboratory's robust quality management system and technical competence but also positions Ghana as a regional leader in medicines quality control, with profound implications for regulatory compliance, trade, and public health outcomes for legal practitioners and stakeholders alike.

The integrity of a nation's public health infrastructure is inextricably linked to the robustness of its regulatory oversight, particularly concerning the safety and quality of food, medicines, and other consumables. In Ghana, the Food and Drugs Authority (FDA) plays this pivotal role, with its Centre for Laboratory Services and Research (CLSR) serving as the scientific bedrock for its regulatory functions. The CLSR's recent advancements, particularly its international accreditations and the landmark World Health Organization (WHO) Prequalification of its Drug Physicochemical Laboratory, mark a significant milestone for Ghana and the broader West African region.

This article delves into the legal and operational significance of the CLSR, examining its foundational statutory framework, its sophisticated laboratory capabilities, and the far-reaching implications of its international recognition. For legal practitioners, understanding the enhanced capabilities and validated standards of the CLSR is crucial for advising clients on regulatory compliance, product liability, and market access within Ghana and across the continent. The thesis of this article is that the CLSR's advanced capabilities are not merely an operational upgrade but a critical development that fundamentally strengthens Ghana's regulatory environment, ensuring public health and elevating its standing as a regional centre of excellence in medical product regulation.

The Food and Drugs Authority (FDA) Ghana operates under a clear legislative mandate, primarily derived from the Public Health Act, 2012 (Act 851). This Act consolidates and updates prior regulations, granting the FDA extensive powers and responsibilities across Parts 6, 7, and 8 to safeguard public health. Specifically, the FDA is tasked with regulating the production, importation, exportation, sale, and distribution of a wide array of products, including human and veterinary drugs, food, biological products, cosmetics, medical devices, household chemicals, and tobacco products, as well as overseeing clinical trials.

Prior to the Public Health Act, the FDA was established as the Food and Drugs Board in 1992 under the Food and Drugs Law, 1992 (PNDCL 305B), which was subsequently amended by the Food and Drugs (Amendment) Act, 1996 (Act 523). This legislative evolution underscores Ghana's progressive commitment to strengthening its regulatory framework. Integral to the FDA's mandate is the provision for laboratory testing, which is explicitly required by the Public Health Act to ensure that all regulated products conform to relevant standards. The Centre for Laboratory Services and Research (CLSR) was thus established as the scientific arm responsible for conducting these vital quality control and assurance tests, thereby underpinning the FDA's ability to enforce standards and protect consumers effectively.

The Centre for Laboratory Services and Research (CLSR) is a sophisticated facility comprising six specialized testing laboratories: Drug Physicochemical, Pharmaceutical Microbiology, Medical Devices, Food Microbiology, Food Physicochemical, and Cosmetic/Household Chemical Substances. Each of these laboratories operates under an integrated Quality Management System (QMS) that adheres to the stringent requirements of ISO/IEC 17025:2017, an international standard for the competence of testing and calibration laboratories. This accreditation signifies the CLSR's technical competence, impartiality, and consistent operation, ensuring the reliability and accuracy of its test results.

A pivotal development for the CLSR occurred in August 2022 when its Drug Physicochemical Laboratory achieved World Health Organization (WHO) Prequalification (PQ) status for chemical testing of medicines. This makes it the first WHO-prequalified national medicines quality control laboratory in the entire West African sub-region. The WHO PQ status is a rigorous endorsement, indicating that the laboratory not only meets ISO/IEC 17025 standards but also complies with WHO's Good Practices for Quality Control Laboratories (GPPQCL) and relevant parts of Good Manufacturing Practices (GMP) for pharmaceutical analysis.

The implications of this WHO Prequalification are profound. Legally, the test results generated by the prequalified laboratory are now internationally recognized and acceptable to all countries, significantly streamlining the process for Ghanaian pharmaceutical products to access global markets and enhancing the credibility of imported medicines. Practically, it positions the CLSR as a regional centre of excellence, capable of providing training and capacity building to other National Medicines Regulatory Authorities (NMRAs) in West Africa. This strengthens regional regulatory harmonization efforts and supports the national vaccine manufacturing agenda by ensuring access to quality, safe, and efficacious vaccines and medicines. Furthermore, the CLSR's enhanced capabilities contribute to the FDA Ghana's overall achievement of WHO Global Benchmarking Tool (GBT) Maturity Level 3, signifying a stable, well-functioning, and integrated regulatory system, a status shared by only a few other African NMRAs. This robust regulatory framework, underpinned by the CLSR's validated testing prowess, enables more effective market surveillance, reduces the incidence of substandard and falsified medical products, and ultimately reinforces consumer confidence in regulated goods.

The Food and Drugs Authority Ghana's Centre for Laboratory Services and Research represents a critical national asset, whose international accreditations and WHO Prequalification status have fundamentally reshaped the regulatory landscape in Ghana and the West African region. For legal practitioners, these developments necessitate a heightened awareness of the stringent quality and safety standards now enforced by the FDA. Manufacturers and importers must ensure their products not only comply with national regulations but also meet internationally recognized benchmarks, as the CLSR's validated testing capabilities will lead to more rigorous enforcement and potentially more complex product liability considerations.

Practitioners should advise clients on the importance of robust internal quality control systems, adherence to Good Manufacturing Practices, and proactive engagement with the FDA's guidelines. The CLSR's role as a regional training hub also signals a future of increased regulatory harmonization across ECOWAS, which could impact cross-border trade and compliance requirements. Legal professionals should closely monitor evolving regulations and regional agreements stemming from Ghana's leadership in this area, preparing clients for an environment where scientific validation and international standards are paramount for market access and sustained operations. The CLSR's achievements underscore a clear call to action for all stakeholders to elevate their commitment to quality and safety, aligning with Ghana's vision to be a global centre of excellence for food and medical product regulation.